The Connections Between Neural Crest Development and Neuroblastoma

Current Topics in Developmental Biology

Volumn 94, Issue C, 2011, Pages 77-127

  Jiang, Manrong ^a   Stanke, Jennifer ^a   Lahti, Jill M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Development; Genetic lesions; N myc amplification; Neural crest; Neuroblastoma; Parasympathetic ganglia

Indexed keywords

MICRORNA; NERVE GROWTH FACTOR; SIGNAL PEPTIDE;

ANIMAL; APOPTOSIS; BOOK; CYTOLOGY; GENETICS; HUMAN; METABOLISM; NEURAL CREST; NEUROBLASTOMA; PATHOLOGY;

ANIMALS; APOPTOSIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; NERVE GROWTH FACTORS; NEURAL CREST; NEUROBLASTOMA;

EID: 79551480067     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-380916-2.00004-8     Document Type: Book

References (281)

1. Abe M., Ohira M., Kaneda A., Yagi Y., Yamamoto S., Kitano Y., Takato T., Nakagawara A., Ushijima T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65:828-834.
2. Abe M., Westermann F., Nakagawara A., Takato T., Schwab M., Ushijima T. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 2007, 247:253-258.
3. Abel F., Sjoberg R.M., Nilsson S., Kogner P., Martinsson T. Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. Eur. J. Cancer 2005, 41:635-646.
4. Adhikary S., Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 2005, 6:635-645.
5. Alenina N., Bashammakh S., Bader M. Specification and differentiation of serotonergic neurons. Stem Cell Rev. 2006, 2:5-10.
6. Almgren M.A., Henriksson K.C., Fujimoto J., Chang C.L. Nucleoside diphosphate kinase A/nm23-H1 promotes metastasis of NB69-derived human neuroblastoma. Mol. Cancer Res. 2004, 2:387-394.
7. Alvarado C.S., London W.B., Look A.T., Brodeur G.M., Altmiller D.H., Thorner P.S., Joshi V.V., Rowe S.T., Nash M.B., Smith E.I., Castleberry R.P., Cohn S.L. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol. 2000, 22:197-205.
8. Anderson D.J. Molecular control of cell fate in the neural crest: The sympathoadrenal lineage. Annu. Rev. Neurosci. 1993, 16:129-158.
9. Anderson D.J., Axel R. A bipotential neuroendocrine precursor whose choice of cell fate is determined by NGF and glucocorticoids. Cell 1986, 47:1079-1090.
10. Anderson D.J., Carnahan J.F., Michelsohn A., Patterson P.H. Antibody markers identify a common progenitor to sympathetic neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal differentiation in the sympathoadrenal lineage. J. Neurosci. 1991, 11:3507-3519.
11. Ando K., Ohira M., Ozaki T., Nakagawa A., Akazawa K., Suenaga Y., Nakamura Y., Koda T., Kamijo T., Murakami Y., Nakagawara A. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int. J. Cancer 2008, 123:2087-2094.
12. Astuti D., Agathanggelou A., Honorio S., Dallol A., Martinsson T., Kogner P., Cummins C., Neumann H.P., Voutilainen R., Dahia P., Eng C., Maher E.R., et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001, 20:7573-7577.
13. Bader S.A., Fasching C., Brodeur G.M., Stanbridge E.J. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ. 1991, 2:245-255.
14. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., Bredel M., Vogel H., Mills A.A. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475.
15. Banelli B., Casciano I., Croce M., di Vinci A., Gelvi I., Pagnan G., Brignole C., Allemanni G., Ferrini S., Ponzoni M., Romani M. Expression and methylation of CASP8 in neuroblastoma: Identification of a promoter region. Nat. Med. 2002, 8:1333-1335.
16. Banerjee S.A., Hoppe P., Brilliant M., Chikaraishi D.M. 5' flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J. Neurosci. 1992, 12:4460-4467.
17. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
18. Beckwith J.B., Perrin E.V. In situ neuroblastomas: A contribution to the natural history of neural crest tumors. Am. J. Pathol. 1963, 43:1089-1104.
19. Beierle E.A., Nagaram A., Dai W., Iyengar M., Chen M.K. VEGF-mediated survivin expression in neuroblastoma cells. J. Surg. Res. 2005, 127:21-28.
20. Benailly H.K., Lapierre J.M., Laudier B., Amiel J., Attie T., De Blois M.C., Vekemans M., Romana S.P. PMX2B, a new candidate gene for Hirschsprung's disease. Clin. Genet. 2003, 64:204-209.
21. Betters E., Liu Y., Kjaeldgaard A., Sundstrom E., Garcia-Castro M. Analysis of early human neural crest development. Dev. Biol. 2010.
22. Blaschke A.J., Weiner J.A., Chun J. Programmed cell death is a universal feature of embryonic and postnatal neuroproliferative regions throughout the central nervous system. J. Comp. Neurol. 1998, 396:39-50.
23. Boatright K.M., Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15:725-731.
24. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell 2003, 11:529-541.
25. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
26. Bourdeaut F., Trochet D., Janoueix-Lerosey I., Ribeiro A., Deville A., Coz C., Michiels J.F., Lyonnet S., Amiel J., Delattre O. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Lett. 2005, 228:51-58.
27. Bourhis J., Benard J., Hartmann O., Boccon-Gibod L., Lemerle J., Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J. Natl. Cancer Inst. 1989, 81:1401-1405.
28. Bown N., Cotterill S., Lastowska M., O'Neill S., Pearson A.D., Plantaz D., Meddeb M., Danglot G., Brinkschmidt C., Christiansen H., Laureys G., Speleman F., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J. Med. 1999, 340:1954-1961.
29. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
30. Breit S., Schwab M. Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J. Neurosci. Res. 1989, 24:21-28.
31. Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
32. Brodeur G.M., Minturn J.E., Ho R., Simpson A.M., Iyer R., Varela C.R., Light J.E., Kolla V., Evans A.E. Trk receptor expression and inhibition in neuroblastomas. Clin. Cancer Res. 2009, 15:3244-3250.
33. Bronner-Fraser M. Neural crest cell migration in the developing embryo. Trends Cell Biol. 1993, 3:392-397.
34. Bronner-Fraser M., Sieber-Blum M., Cohen A.M. Clonal analysis of the avian neural crest: Migration and maturation of mixed neural crest clones injected into host chicken embryos. J. Comp. Neurol. 1980, 193:423-434.
35. Caren H., Abel F., Kogner P., Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 2008, 416:153-159.
36. Caron H., van S.P., Buschman R., Pereira do T.R., Maes P., Beks L., de K.J., Voute P.A., Vergnaud G., Westerveld A., Slater R., Versteeg R. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum. Genet. 1996, 97:834-837.
37. Castle V.P., Heidelberger K.P., Bromberg J., Ou X., Dole M., Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 1993, 143:1543-1550.
38. Castleberry R.P., Pritchard J., Ambros P., Berthold F., Brodeur G.M., Castel V., Cohn S.L., De B.B., Cks-Mireaux C., Frappaz D., Haase G.M., Haber M., et al. The International Neuroblastoma Risk Groups (INRG): A preliminary repor. Eur. J. Cancer 1997, 33:2113-2116.
39. Chambery D., Mohseni-Zadeh S., de G.B., Babajko S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res. 1999, 59:2898-2902.
40. Chan H.S., Haddad G., Thorner P.S., DeBoer G., Lin Y.P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J. Med. 1991, 325:1608-1614.
41. Chang C.L., Strahler J.R., Thoraval D.H., Qian M.G., Hinderer R., Hanash S.M. A nucleoside diphosphate kinase A (nm23-H1) serine 120->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction. Oncogene 1996, 12:659-667.
42. Charron J., Malynn B.A., Fisher P., Stewart V., Jeannotte L., Goff S.P., Robertson E.J., Alt F.W. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev. 1992, 6:2248-2257.
43. Chen Y., Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007, 67:976-983.
44. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
45. Chen L., Iraci N., Gherardi S., Gamble L.D., Wood K.M., Perini G., Lunec J., Tweddle D.A. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res. 2010, 70:1377-1388.
46. Cheng M., Ott G.R. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anticancer Agents Med. Chem. 2010, 10:236-249.
47. Cohn S.L., Pearson A.D., London W.B., Monclair T., Ambros P.F., Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., Mosseri V., Simon T., et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 2009, 27:289-297.
48. Combaret V., Gross N., Lasset C., Frappaz D., Peruisseau G., Philip T., Beck D., Favrot M.C. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J. Clin. Oncol. 1996, 14:25-34.
49. Coppola D., Ouban A., Gilbert-Barness E. Expression of the insulin-like growth factor receptor 1 during human embryogenesis. Fetal Pediatr. Pathol. 2009, 28:47-54.
50. Corvi R., Savelyeva L., Amler L., Handgretinger R., Schwab M. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Eur. J. Cancer 1995, 31A:520-523.
51. Corvi R., Savelyeva L., Schwab M. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells. Cancer Res. 1995, 55:3471-3474.
52. Coulter D.W., Wilkie M.B., Moats-Staats B.M. Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation. Anticancer Res. 2009, 29:1943-1949.
53. Cui H., Li T., Ding H.F. Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem. 2005, 280:9474-9481.
54. Danial N.N., Korsmeyer S.J. Cell death: Critical control points. Cell 2004, 116:205-219.
55. De Zio D., Giunta L., Corvaro M., Ferraro E., Cecconi F. Expanding roles of programmed cell death in mammalian neurodevelopment. Semin. Cell Dev. Biol. 2005, 16:281-294.
56. De Cremoux P., Jourdan-Da-Silva N., Couturier J., Tran-Perennou C., Schleiermacher G., Fehlbaum P., Doz F., Mosseri V., Delattre O., Klijanienko J., Vielh P., Michon J. Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr. Blood Cancer 2007, 48:311-317.
57. Degoutin J., Brunet-de C.N., Cifuentes-Diaz C., Vigny M. ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction. Eur. J. Neurosci. 2009, 29:275-286.
58. D'Ercole A.J., Ye P., Calikoglu A.S., Gutierrez-Ospina G. The role of the insulin-like growth factors in the central nervous system. Mol. Neurobiol. 1996, 13:227-255.
59. Dhooge C.R., De Moerloose B.M., Benoit Y.C., Van R.N., Philippe G.G. Laureys, Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer 1997, 80:1250-1257.
60. Dole M., Nunez G., Merchant A.K., Maybaum J., Rode C.K., Bloch C.A., Castle V.P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994, 54:3253-3259.
61. Dole M.G., Jasty R., Cooper M.J., Thompson C.B., Nunez G., Castle V.P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 1995, 55:2576-2582.
62. Douma S., Van L.T., Zevenhoven J., Meuwissen R., Van G.E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
63. Dupin E., Calloni G., Real C., Goncalves-Trentin A., Le Douarin N.M. Neural crest progenitors and stem cells. C. R. Biol. 2007, 330:521-529.
64. Ejeskar K., Aburatani H., Abrahamsson J., Kogner P., Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br. J. Cancer 1998, 77:1787-1791.
65. Emanuel B.S., Balaban G., Boyd J.P., Grossman A., Negishi M., Parmiter A., Glick M.C. N-myc amplification in multiple homogeneously staining regions in two human neuroblastomas. Proc. Natl. Acad. Sci. USA 1985, 82:3736-3740.
66. Erickson C.A., Turley E.A. The effects of epidermal growth factor on neural crest cells in tissue culture. Exp. Cell Res. 1987, 169:267-279.
67. Ernsberger U., Esposito L., Partimo S., Huber K., Franke A., Bixby J.L., Kalcheim C., Unsicker K. Expression of neuronal markers suggests heterogeneity of chick sympathoadrenal cells prior to invasion of the adrenal anlagen. Cell Tissue Res. 2005, 319:1-13.
68. Evans A.E., D'Angio G.J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 1971, 27:374-378.
69. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 2003, 17:1115-1129.
70. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
71. Fontaine-Perus J.C., Chanconie M., Le Douarin N.M. Differentiation of peptidergic neurones in quail-chick chimaeric embryos. Cell Differ. 1982, 11:183-193.
72. Fulda S., Debatin K.M. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006, 25:5125-5133.
73. Fulda S., Lutz W., Schwab M., Debatin K.M. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999, 18:1479-1486.
74. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877.
75. Gebeshuber C.A., Zatloukal K., Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009, 10:400-405.
76. George R.E., Kenyon R.M., McGuckin A.G., Malcolm A.J., Pearson A.D., Lunec J. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. Oncogene 1996, 12:1583-1587.
77. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
78. Gilbert F., Feder M., Balaban G., Brangman D., Lurie D.K., Podolsky R., Rinaldt V., Vinikoor N., Weisband J. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984, 44:5444-5449.
79. Godfried M.B., Veenstra M., Sluis P., Boon K., Asperen R., Hermus M.C., Schaik B.D., Voute T.P., Schwab M., Versteeg R., Caron H.N. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 2002, 21:2097-2101.
80. Gomyo H., Arai Y., Tanigami A., Murakami Y., Hattori M., Hosoda F., Arai K., Aikawa Y., Tsuda H., Hirohashi S., Asakawa S., Shimizu N., et al. A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11q23.2. Genomics 1999, 62:139-146.
81. Gonzalez-Gomez P., Bello M.J., Inda M.M., Alonso M.E., Arjona D., Aminoso C., Lopez-Marin I., de Campos J.M., Sarasa J.L., Castresana J.S., Rey J.A. Deletion and aberrant CpG island methylation of Caspase 8 gene in medulloblastoma. Oncol. Rep. 2004, 12:663-666.
82. Goto H., Keshelava N., Matthay K.K., Lukens J.N., Gerbing R.B., Stram D.O., Seeger R.C., Reynolds C.P. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med. Pediatr. Oncol. 2000, 35:619-622.
83. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629.
84. Grenet J., Teitz T., Wei T., Valentine V., Kidd V.J. Structure and chromosome localization of the human CASP8 gene. Gene 1999, 226:225-232.
85. Grimmer M.R., Weiss W.A. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr. 2006, 18:634-638.
86. Guo C., White P.S., Weiss M.J., Hogarty M.D., Thompson P.M., Stram D.O., Gerbing R., Matthay K.K., Seeger R.C., Brodeur G.M., Maris J.M. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999, 18:4948-4957.
87. Guo J., Dong Q., Fang Z., Chen X., Lu H., Wang K., Yin Y., Cai X., Zhao N., Chen J., Zen K., Zhang J., et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol. Ther. 2010, 9:446-452.
88. Haase G.M., Perez C., Atkinson J.B. Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin. Surg. Oncol. 1999, 16:91-104.
89. Haber M., Bordow S.B., Gilbert J., Madafiglio J., Kavallaris M., Marshall G.M., Mechetner E.B., Fruehauf J.P., Tee L., Cohn S.L., Salwen H., Schmidt M.L., et al. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 1999, 18:2777-2782.
90. Haber M., Smith J., Bordow S.B., Flemming C., Cohn S.L., London W.B., Marshall G.M., Norris M.D. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 2006, 24:1546-1553.
91. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999, 5:1164-1170.
92. Harada K., Toyooka S., Shivapurkar N., Maitra A., Reddy J.L., Matta H., Miyajima K., Timmons C.F., Tomlinson G.E., Mastrangelo D., Hay R.J., Chaudhary P.M., et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002, 62:5897-5901.
93. Harris R.G., White E., Phillips E.S., Lillycrop K.A. The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. J. Biol. Chem. 2002, 277:34815-34825.
94. Hatzi E., Murphy C., Zoephel A., Ahorn H., Tontsch U., Bamberger A.M., Yamauchi-Takihara K., Schweigerer L., Fotsis T. N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. Eur. J. Biochem. 2002, 269:3732-3741.
95. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., Yatabe Y., Kawahara K., Sekido Y., Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65:9628-9632.
96. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
97. He L., He X., Lim L.P., de S.E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A.L., Linsley P.S., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
98. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
99. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cell. Signal. 2006, 18:2089-2097.
100. Hirai M., Yoshida S., Kashiwagi H., Kawamura T., Ishikawa T., Kaneko M., Ohkawa H., Nakagawara A., Miwa M., Uchida K. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. Genes Chromosom. Cancer 1999, 25:261-269.
101. Hiyama E., Hiyama K., Ohtsu K., Yamaoka H., Ichikawa T., Shay J.W., Yokoyama T. Telomerase activity in neuroblastoma: Is it a prognostic indicator of clinical behaviour?. Eur. J. Cancer 1997, 33:1932-1936.
102. Ho R., Eggert A., Hishiki T., Minturn J.E., Ikegaki N., Foster P., Camoratto A.M., Evans A.E., Brodeur G.M. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002, 62:6462-6466.
103. Ho R., Minturn J.E., Hishiki T., Zhao H., Wang Q., Cnaan A., Maris J., Evans A.E., Brodeur G.M. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005, 65:9868-9875.
104. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med. Pediatr. Oncol. 2000, 35:608-611.
105. Hopkins-Donaldson S., Ziegler A., Kurtz S., Bigosch C., Kandioler D., Ludwig C., Zangemeister-Wittke U., Stahel R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003, 10:356-364.
106. Howard M.J., Stanke M., Schneider C., Wu X., Rohrer H. The transcription factor dHAND is a downstream effector of BMPs in sympathetic neuron specification. Development 2000, 127:4073-4081.
107. Huber K. The sympathoadrenal cell lineage: Specification, diversification, and new perspectives. Dev. Biol. 2006, 298:335-343.
108. Huber K., Franke A., Bruhl B., Krispin S., Ernsberger U., Schober A., von Bohlen und H.O., Rohrer H., Kalcheim C., Unsicker K. Persistent expression of BMP-4 in embryonic chick adrenal cortical cells and its role in chromaffin cell development. Neural Dev. 2008, 3:28.
109. Hurley S.P., Clary D.O., Copie V., Lefcort F. Anaplastic lymphoma kinase is dynamically expressed on subsets of motor neurons and in the peripheral nervous system. J. Comp. Neurol. 2006, 495:202-212.
110. Hurlin P.J. N-Myc functions in transcription and development. Birth Defects Res. C Embryo Today 2005, 75:340-352.
111. Ichimiya S., Nimura Y., Kageyama H., Takada N., Sunahara M., Shishikura T., Nakamura Y., Sakiyama S., Seki N., Ohira M., Kaneko Y., McKeon F., et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 1999, 18:1061-1066.
112. Ikegaki N., Katsumata M., Tsujimoto Y., Nakagawara A., Brodeur G.M. Relationship between bcl-2 and myc gene expression in human neuroblastoma. Cancer Lett. 1995, 91:161-168.
113. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., Ohira M., Hashizume K., Kobayashi H., Kaneko Y., Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
114. Iwahara T., Fujimoto J., Wen D., Cupples R., Bucay N., Arakawa T., Mori S., Ratzkin B., Yamamoto T. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997, 14:439-449.
115. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., De P.L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
116. Jinbo T., Iwamura Y., Kaneko M., Sawaguchi S. Coamplification of the L-myc and N-myc oncogenes in a neuroblastoma cell line. Jpn J. Cancer Res. 1989, 80:299-301.
117. Johnsen J.I., Pettersen I., Ponthan F., Sveinbjornsson B., Flaegstad T., Kogner P. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int. J. Oncol. 2004, 25:1849-1857.
118. Johnsen J.I., Kogner P., Albihn A., Henriksson M.A. Embryonal neural tumours and cell death. Apoptosis 2009, 14:424-438.
119. Kang Y., Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 2004, 118:277-279.
120. Kaufmann S.H., Vaux D.L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22:7414-7430.
121. Kelleher F.C., McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur. J. Cancer 2010, 46, 2357-2368.
122. Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001, 61:6185-6193.
123. Kim C.J., Matsuo T., Lee K.H., Thiele C.J. Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells. Am. J. Pathol. 1999, 155:1661-1670.
124. Kim H.S., Lee J.W., Soung Y.H., Park W.S., Kim S.Y., Lee J.H., Park J.Y., Cho Y.G., Kim C.J., Jeong S.W., Nam S.W., Kim S.H., et al. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 2003, 125:708-715.
125. Klefstrom J., Verschuren E.W., Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J. Biol. Chem. 2002, 277:43224-43232.
126. Knoepfler P.S., Cheng P.F., Eisenman R.N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 2002, 16:2699-2712.
127. Kohl N.E., Kanda N., Schreck R.R., Bruns G., Latt S.A., Gilbert F., Alt F.W. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983, 35:359-367.
128. Krelin Y., Zhang L., Kang T.B., Appel E., Kovalenko A., Wallach D. Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ. 2008, 15:1350-1355.
129. Kulesa P., Ellies D.L., Trainor P.A. Comparative analysis of neural crest cell death, migration, and function during vertebrate embryogenesis. Dev. Dyn. 2004, 229:14-29.
130. Kutlik M.T., Ayhan A., Gogus S., Yalcin B., Caglar M., Buyukpamukcu M. Glutathione S-transferase and P-glycoprotein expressions in neuroblastoma. Pediatr. Hematol. Oncol. 2002, 19:337-345.
131. LaBrosse E.H., Comoy E., Bohuon C., Zucker J.M., Schweisguth O. Catecholamine metabolism in neuroblastoma. J. Natl. Cancer Inst. 1976, 57:633-638.
132. Lahti J.M., Teitz T., Stupack D.G. Does integrin-mediated cell death confer tissue tropism in metastasis?. Cancer Res. 2006, 66:5981-5984.
133. Lallier T.E., Bronner-Fraser M. A spatial and temporal analysis of dorsal root and sympathetic ganglion formation in the avian embryo. Dev. Biol. 1988, 127:99-112.
134. Lasorella A., Boldrini R., Dominici C., Donfrancesco A., Yokota Y., Inserra A., Iavarone A. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res. 2002, 62:301-306.
135. Lastowska M., Nacheva E., McGuckin A., Curtis A., Grace C., Pearson A., Bown N. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group, Genes Chromosomes. Cancer 1997, 18:162-169.
136. Le Dourin N.M., Kalcheim G. The Neural Crest 1999, Cambridge University Press. 2nd edn.
137. Lee W.H., Murphree A.L., Benedict W.F. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 1984, 309:458-460.
138. Lutz W., Stohr M., Schurmann J., Wenzel A., Lohr A., Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996, 13:803-812.
139. Lutz W., Fulda S., Jeremias I., Debatin K.M., Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998, 17:339-346.
140. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
141. Mac S.M., D'Cunha C.A., Farnham P.J. Direct recruitment of N-myc to target gene promoters. Mol. Carcinog. 2000, 29:76-86.
142. Maris J.M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr. 2005, 17:7-13.
143. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 1999, 17:2264-2279.
144. Maris J.M., Weiss M.J., Mosse Y., Hii G., Guo C., White P.S., Hogarty M.D., Mirensky T., Brodeur G.M., Rebbeck T.R., Urbanek M., Shusterman S. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002, 62:6651-6658.
145. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
146. Marshall B., Isidro G., Martins A.G., Boavida M.G. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: Evidence for two deleted regions. Cancer Genet. Cytogenet. 1997, 96:134-139.
147. Martin D.M., Yee D., Carlson R.O., Feldman E.L. Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. Brain Res. Mol. Brain Res. 1992, 15:241-246.
148. Martinez R., Setien F., Voelter C., Casado S., Quesada M.P., Schackert G., Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007, 28:1264-1268.
149. Matsuo N., Shiraha H., Fujikawa T., Takaoka N., Ueda N., Tanaka S., Nishina S., Nakanishi Y., Uemura M., Takaki A., Nakamura S., Kobayashi Y., et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009, 9:240.
150. Matthay K.K. Neuroblastoma: A clinical challenge and biologic puzzle. CA Cancer J. Clin. 1995, 45:179-192.
151. Matthay K.K., Perez C., Seeger R.C., Brodeur G.M., Shimada H., Atkinson J.B., Black C.T., Gerbing R., Haase G.M., Stram D.O., Swift P., Lukens J.N. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J. Clin. Oncol. 1998, 16:1256-1264.
152. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J. Med. 1999, 341:1165-1173.
153. McConkey D.J., Choi W., Marquis L., Martin F., Williams M.B., Shah J., Svatek R., Das A., Adam L., Kamat A., Siefker-Radtke A., Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009, 28:335-344.
154. McLennan R., Teddy J.M., Kasemeier-Kulesa J.C., Romine M.H., Kulesa P.M. Vascular endothelial growth factor (VEGF) regulates cranial neural crest migration in vivo. Dev. Biol. 2010, 339:114-125.
155. Meddeb M., Danglot G., Chudoba I., Venuat A.M., Benard J., vet-Loiseau H., Vasseur B., Le P.D., Terrier-Lacombe M.J., Hartmann O., Bernheim A. Additional copies of a 25Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas, Genes Chromosomes. Cancer 1996, 17:156-165.
156. Mejia M.C., Navarro S., Pellin A., Castel V., Llombart-Bosch A. Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res. 1998, 18:801-806.
157. Meltzer S.J., O'Doherty S.P., Frantz C.N., Smolinski K., Yin J., Cantor A.B., Liu J., Valentine M., Brodeur G.M., Berg P.E. Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma. Br. J. Cancer 1996, 74:1855-1861.
158. Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., Kaneko M., London W.B., Matthay K.K., Nuchtern J.G., von S.D., Simon T., et al. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J. Clin. Oncol. 2009, 27:298-303.
159. Mora J., Cheung N.K., Chen L., Qin J., Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin. Cancer Res. 2001, 7:1358-1361.
160. Morales A.V., Barbas J.A., Nieto M.A. How to become neural crest: From segregation to delamination. Semin. Cell Dev. Biol. 2005, 16:655-662.
161. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
162. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., Witte D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14:2175-2188.
163. Mosse Y.P., Laudenslager M., Khazi D., Carlisle A.J., Winter C.L., Rappaport E., Maris J.M. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 2004, 75:727-730.
164. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
165. Mosse Y.P., Wood A., Maris J.M. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res. 2009, 15:5609-5614.
166. Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 2004, 117:3319-3329.
167. Muhlethaler-Mottet A., Balmas K., Auderset K., Joseph J.M., Gross N. Restoration of TRAIL-induced apoptosis in a caspase-8-deficient neuroblastoma cell line by stable re-expression of caspase-8. Ann. NY Acad. Sci. 2003, 1010:195-199.
168. Munchar M.J., Sharifah N.A., Jamal R., Looi L.M. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours. Pathology 2003, 35:125-129.
169. Munirajan A.K., Ando K., Mukai A., Takahashi M., Suenaga Y., Ohira M., Koda T., Hirota T., Ozaki T., Nakagawara A. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J. Biol. Chem. 2008, 283:24426-24434.
170. Nakagawara A. Neural crest development and neuroblastoma: The genetic and biological link. Prog. Brain Res. 2004, 146:233-242.
171. Nakagawara A., Ohira M. Comprehensive genomics linking between neural development and cancer: Neuroblastoma as a model. Cancer Lett. 2004, 204:213-224.
172. Nakagawara A., Arima M., Azar C.G., Scavarda N.J., Brodeur G.M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 1992, 52:1364-1368.
173. Nakagawara A., rima-Nakagawara M., Scavarda N.J., Azar C.G., Cantor A.B., Brodeur G.M. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J. Med. 1993, 328:847-854.
174. Nakagawara A., Azar C.G., Scavarda N.J., Brodeur G.M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell. Biol. 1994, 14:759-767.
175. Nakagawara A., rima-Nakagawara M., Azar C.G., Scavarda N.J., Brodeur G.M. Clinical significance of expression of neurotrophic factors and their receptors in neuroblastoma. Prog. Clin. Biol. Res. 1994, 385:155-161.
176. Nieminen A.I., Partanen J.I., Klefstrom J. c-Myc blazing a trail of death: Coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 2007, 6:2464-2472.
177. Norris M.D., Bordow S.B., Marshall G.M., Haber P.S., Cohn S.L., Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J. Med. 1996, 334:231-238.
178. Norris M.D., Smith J., Tanabe K., Tobin P., Flemming C., Scheffer G.L., Wielinga P., Cohn S.L., London W.B., Marshall G.M., Allen J.D., Haber M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther. 2005, 4:547-553.
179. Nowak K., Kerl K., Fehr D., Kramps C., Gessner C., Killmer K., Samans B., Berwanger B., Christiansen H., Lutz W. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006, 34:1745-1754.
180. Ochiai H., Takenobu H., Nakagawa A., Yamaguchi Y., Kimura M., Ohira M., Okimoto Y., Fujimura Y., Koseki H., Kohno Y., Nakagawara A., Kamijo T. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 2010, 29:2681-2690.
181. Ohali A., Avigad S., Ash S., Goshen Y., Luria D., Feinmesser M., Zaizov R., Yaniv I. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006, 107:1391-1399.
182. Okabe-Kado J., Kasukabe T., Honma Y., Hanada R., Nakagawara A., Kaneko Y. Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci. 2005, 96:653-660.
183. Osajima-Hakomori Y., Miyake I., Ohira M., Nakagawara A., Nakagawa A., Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 2005, 167:213-222.
184. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: Signalling in development and disease. Biochem. J. 2009, 420:345-361.
185. Park J.R., Eggert A., Caron H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr. Clin. North Am. 2008, 55:97-120. (x).
186. Passoni L., Longo L., Collini P., Coluccia A.M., Bozzi F., Podda M., Gregorio A., Gambini C., Garaventa A., Pistoia V., Del G.F., Tonini G.P., et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009, 69:7338-7346.
187. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 2008, 9:247-256.
188. Pelengaris S., Khan M., Evan G. c-MYC: More than just a matter of life and death. Nat. Rev. Cancer 2002, 2:764-776.
189. Perini G., Diolaiti D., Porro A., Della V.G. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc. Natl. Acad. Sci. USA 2005, 102:12117-12122.
190. Perri P., Longo L., Cusano R., McConville C.M., Rees S.A., Devoto M., Conte M., Ferrara G.B., Seri M., Romeo G., Tonini G.P. Weak linkage at 4p16 to predisposition for human neuroblastoma. Oncogene 2002, 21:8356-8360.
191. Pingoud-Meier C., Lang D., Janss A.J., Rorke L.B., Phillips P.C., Shalaby T., Grotzer M.A. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer Res. 2003, 9:6401-6409.
192. Raabe E.H., Laudenslager M., Winter C., Wasserman N., Cole K., LaQuaglia M., Maris D.J., Mosse Y.P., Maris J.M. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008, 27:469-476.
193. Ramani P., Lu Q.L. Expression of bcl-2 gene product in neuroblastoma. J. Pathol. 1994, 172:273-278.
194. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: Mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006, 13:1378-1386.
195. Reed J.C., Tomaselli K.J. Drug discovery opportunities from apoptosis research. Curr. Opin. Biotechnol. 2000, 11:586-592.
196. Reissmann E., Ernsberger U., Francis-West P.H., Rueger D., Brickell P.M., Rohrer H. Involvement of bone morphogenetic protein-4 and bone morphogenetic protein-7 in the differentiation of the adrenergic phenotype in developing sympathetic neurons. Development 1996, 122:2079-2088.
197. Reiter J.L., Brodeur G.M. High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. Genomics 1996, 32:97-103.
198. Reiter J.L., Brodeur G.M. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosom. Cancer 1998, 23:134-140.
199. Reynolds C.P., Zuo J.J., Kim N.W., Wang H., Lukens J.N., Matthay K.K., Seeger R.C. Telomerase expression in primary neuroblastomas. Eur. J. Cancer 1997, 33:1929-1931.
200. Ribatti D., Marimpietri D., Pastorino F., Brignole C., Nico B., Vacca A., Ponzoni M. Angiogenesis in neuroblastoma. Ann. NY Acad. Sci. 2004, 1028:133-142.
201. Ruffins S., Artinger K.B., Bronner-Fraser M. Early migrating neural crest cells can form ventral neural tube derivatives when challenged by transplantation. Dev. Biol. 1998, 203:295-304.
202. Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003, 63:1876-1883.
203. Salvesen G.S., Abrams J.M. Caspase activation-Stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 2004, 23:2774-2784.
204. Sawada T. Past and future of neuroblastoma screening in Japan. Am. J. Pediatr. Hematol. Oncol. 1992, 14:320-326.
205. Sawai S., Shimono A., Hanaoka K., Kondoh H. Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes. New Biol. 1991, 3:861-869.
206. Sawai S., Shimono A., Wakamatsu Y., Palmes C., Hanaoka K., Kondoh H. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 1993, 117:1445-1455.
207. Scaruffi P., Valent A., Schramm A., Astrahantseff K., Eggert A., Tonini G.P. Application of microarray-based technology to neuroblastoma. Cancer Lett. 2005, 228:13-20.
208. Schlisio S., Kenchappa R.S., Vredeveld L.C., George R.E., Stewart R., Greulich H., Shahriari K., Nguyen N.V., Pigny P., Dahia P.L., Pomeroy S.L., Maris J.M., et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008, 22:884-893.
209. Schmidt M.L., Lukens J.N., Seeger R.C., Brodeur G.M., Shimada H., Gerbing R.B., Stram D.O., Perez C., Haase G.M., Matthay K.K. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J. Clin. Oncol. 2000, 18:1260-1268.
210. Schneider C., Wicht H., Enderich J., Wegner M., Rohrer H. Bone morphogenetic proteins are required in vivo for the generation of sympathetic neurons. Neuron 1999, 24:861-870.
211. Schonherr C., Yang H.L., Vigny M., Palmer R.H., Hallberg B. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells. Oncogene 2010, 29:2817-2830.
212. Schor N.F. Neuroblastoma as a neurobiological disease. J. Neurooncol. 1999, 41:159-166.
213. Schor N.F. New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol. Ther. 2009, 122:44-55.
214. Schulte J.H., Horn S., Otto T., Samans B., Heukamp L.C., Eilers U.C., Krause M., Astrahantseff K., Klein-Hitpass L., Buettner R., Schramm A., Christiansen H., et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int. J. Cancer 2008, 122:699-704.
215. Schwab M., Alitalo K., Klempnauer K.H., Varmus H.E., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983, 305:245-248.
216. Schwab M., Varmus H.E., Bishop J.M., Grzeschik K.H., Naylor S.L., Sakaguchi A.Y., Brodeur G., Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984, 308:288-291.
217. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
218. Shah N.M., Groves A.K., Anderson D.J. Alternative neural crest cell fates are instructively promoted by TGFbeta superfamily members. Cell 1996, 85:331-343.
219. Shi Y. Caspase activation: Revisiting the induced proximity model. Cell 2004, 117:855-858.
220. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86:364-372.
221. Shimono R., Matsubara S., Takamatsu H., Fukushige T., Ozawa M. The expression of cadherins in human neuroblastoma cell lines and clinical tumors. Anticancer Res. 2000, 20:917-923.
222. Shohet J.M., Hicks M.J., Plon S.E., Burlingame S.M., Stuart S., Chen S.Y., Brenner M.K., Nuchtern J.G. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002, 62:1123-1128.
223. Shtivelman E., Bishop J.M. Expression of CD44 is repressed in neuroblastoma cells. Mol. Cell. Biol. 1991, 11:5446-5453.
224. Simon T., Spitz R., Faldum A., Hero B., Berthold F. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J. Pediatr. Hematol. Oncol. 2004, 26:791-796.
225. Slack A., Chen Z., Tonelli R., Pule M., Hunt L., Pession A., Shohet J.M. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl. Acad. Sci. USA 2005, 102:731-736.
226. Sosic D., Olson E.N. A new twist on twist-modulation of the NF-kappa B pathway. Cell Cycle 2003, 2:76-78.
227. Soung Y.H., Lee J.W., Kim S.Y., Jang J., Park Y.G., Park W.S., Nam S.W., Lee J.Y., Yoo N.J., Lee S.H. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 2005, 65:815-821.
228. Souttou B., Carvalho N.B., Raulais D., Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 2001, 276:9526-9531.
229. Stanton B.R., Perkins A.S., Tessarollo L., Sassoon D.A., Parada L.F. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 1992, 6:2235-2247.
230. Straub J.A., Sholler G.L., Nishi R. Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro. BMC Dev. Biol. 2007, 7:10.
231. Strieder V., Lutz W. E2F proteins regulate MYCN expression in neuroblastomas. J. Biol. Chem. 2003, 278:2983-2989.
232. Stupack D.G., Teitz T., Potter M.D., Mikolon D., Houghton P.J., Kidd V.J., Lahti J.M., Cheresh D.A. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006, 439:95-99.
233. Sugiura Y., Shimada H., Seeger R.C., Laug W.E., DeClerck Y.A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998, 58:2209-2216.
234. Suzuki T., Yokota J., Mugishima H., Okabe I., Ookuni M., Sugimura T., Terada M. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res. 1989, 49:1095-1098.
235. Svensson T., Ryden M., Schilling F.H., Dominici C., Sehgal R., Ibanez C.F., Kogner P. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma. Eur. J. Cancer 1997, 33:2058-2063.
236. Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A., Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A., Mackay A.R. TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004, 6:347-360.
237. Takita J., Hayashi Y., Takei K., Yamaguchi N., Hanada R., Yamamoto K., Yokota J. Allelic imbalance on chromosome 18 in neuroblastoma. Eur. J. Cancer 2000, 36:508-513.
238. Takita J., Yang H.W., Chen Y.Y., Hanada R., Yamamoto K., Teitz T., Kidd V., Hayashi Y. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 2001, 20:4424-4432.
239. Tanabe K.K., Ellis L.M., Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993, 341:725-726.
240. Teillet M.A., Kalcheim C., Le Douarin N.M. Formation of the dorsal root ganglia in the avian embryo: Segmental origin and migratory behavior of neural crest progenitor cells. Dev. Biol. 1987, 120:329-347.
241. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., Kidd V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000, 6:529-535.
242. Teitz T., Lahti J.M., Kidd V.J. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J. Mol. Med. 2001, 79:428-436.
243. Teitz T., Stupack D.G., Lahti J.M. Halting neuroblastoma metastasis by controlling integrin-mediated death. Cell Cycle 2006, 5:681-685.
244. Tekautz T.M., Zhu K., Grenet J., Kaushal D., Kidd V.J., Lahti J.M. Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma-preclinical studies. Biochim. Biophys. Acta 2006, 1763:1000-1010.
245. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
246. Thompson E.B. The many roles of c-Myc in apoptosis. Annu. Rev. Physiol. 1998, 60:575-600.
247. Thompson P.M., Seifried B.A., Kyemba S.K., Jensen S.J., Guo C., Maris J.M., Brodeur G.M., Stram D.O., Seeger R.C., Gerbing R., Matthay K.K., Matise T.C., et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med. Pediatr. Oncol. 2001, 36:28-31.
248. Treins C., Giorgetti-Peraldi S., Murdaca J., Monthouel-Kartmann M.N., Van O.E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Mol. Endocrinol. 2005, 19:1304-1317.
249. Trochet D., Bourdeaut F., Janoueix-Lerosey I., Deville A., de P.L., Schleiermacher G., Coze C., Philip N., Frebourg T., Munnich A., Lyonnet S., Delattre O., et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 2004, 74:761-764.
250. Trochet D., Hong S.J., Lim J.K., Brunet J.F., Munnich A., Kim K.S., Lyonnet S., Goridis C., Amiel J. Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum. Mol. Genet. 2005, 14:3697-3708.
251. Trochet D., Mathieu Y., Pontual L., Savarirayan R., Munnich A., Brunet J.F., Lyonnet S., Goridis C., Amiel J. In vitro studies of non poly alanine PHOX2B mutations argue against a loss-of-function mechanism for congenital central hypoventilation. Hum. Mutat. 2009, 30:E421-E431.
252. Tweddle D.A., Pearson A.D., Haber M., Norris M.D., Xue C., Flemming C., Lunec J. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003, 197:93-98.
253. Valdes-Mora F., Gomez Del P.T., Bandres E., Cejas P., Ramirez De M.A., Perez-Palacios R., Gallego-Ortega D., Garcia-Cabezas M.A., Casado E., Larrauri J., Nistal M., Gonzalez-Baron M., et al. TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann. Surg. Oncol. 2009, 16:78-87.
254. Valentinis B., Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol. Pathol. 2001, 54:133-137.
255. Valsesia-Wittmann S., Magdeleine M., Dupasquier S., Garin E., Jallas A.C., Combaret V., Krause A., Leissner P., Puisieux A. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004, 6:625-630.
256. van Golen C.M., Schwab T.S., Kim B., Soules M.E., Su O.S., Fung K., van Golen K.L., Feldman E.L. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res. 2006, 66:6570-6578.
257. van Noesel M.M., Versteeg R. Pediatric neuroblastomas: Genetic and epigenetic 'danse macabre'. Gene 2004, 325:1-15.
258. van Noesel M.M., van Bezouw S., Salomons G.S., Voute P.A., Pieters R., Baylin S.B., Herman J.G., Versteeg R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 2002, 62:2157-2161.
259. Van R.N., Forus A., Myklebost O., Cheng N.C., Versteeg R., Speleman F. Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Cancer Genet. Cytogenet. 1995, 82:151-154.
260. Vandesompele J., Van R.N., Van G.M., Laureys G., Ambros P., Heimann P., Devalck C., Schuuring E., Brock P., Otten J., Gyselinck J., De P.A., et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosom. Cancer 1998, 23:141-152.
261. Vega S., Morales A.V., Ocana O.H., Valdes F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004, 18:1131-1143.
262. Vernersson E., Khoo N.K., Henriksson M.L., Roos G., Palmer R.H., Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 2006, 6:448-461.
263. Vitali R., Mancini C., Cesi V., Tanno B., Mancuso M., Bossi G., Zhang Y., Martinez R.V., Calabretta B., Dominici C., Raschella G. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin. Cancer Res. 2008, 14:4622-4630.
264. Wada R.K., Seeger R.C., Reynolds C.P., Alloggiamento T., Yamashiro J.M., Ruland C., Black A.C., Rosenblatt J.D. Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene 1992, 7:711-717.
265. Wagner L.M., Danks M.K. New therapeutic targets for the treatment of high-risk neuroblastoma. J. Cell. Biochem. 2009, 107:46-57.
266. Wakamatsu Y., Watanabe Y., Nakamura H., Kondoh H. Regulation of the neural crest cell fate by N-myc: Promotion of ventral migration and neuronal differentiation. Development 1997, 124:1953-1962.
267. Wartiovaara K., Barnabe-Heider F., Miller F.D., Kaplan D.R. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. J. Neurosci. 2002, 22:815-824.
268. Wei J.S., Song Y.K., Durinck S., Chen Q.R., Cheuk A.T., Tsang P., Zhang Q., Thiele C.J., Slack A., Shohet J., Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213.
269. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
270. Welch C., Chen Y., Stallings R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26:5017-5022.
271. WESTON J.A. A radioautographic analysis of the migration and localization of trunk neural crest cells in the chick. Dev. Biol. 1963, 6:279-310.
272. Witt O., Deubzer H.E., Lodrini M., Milde T., Oehme I. Targeting histone deacetylases in neuroblastoma. Curr. Pharm. Des. 2009, 15:436-447.
273. Xue C., Haber M., Flemming C., Marshall G.M., Lock R.B., MacKenzie K.L., Gurova K.V., Norris M.D., Gudkov A.V. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 2007, 67:10351-10360.
274. Yamashiro D.J., Nakagawara A., Ikegaki N., Liu X.G., Brodeur G.M. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996, 12:37-41.
275. Yang Q.W., Liu S., Tian Y., Salwen H.R., Chlenski A., Weinstein J., Cohn S.L. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63:6299-6310.
276. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
277. Yang Q., Kiernan C.M., Tian Y., Salwen H.R., Chlenski A., Brumback B.A., London W.B., Cohn S.L. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin. Cancer Res. 2007, 13:3191-3197.
278. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S., Chen H.X., Matthay K.K., Cohn S.L., Maris J.M., Sondel P. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J. Clin. Oncol. 2009, 27:15s. (suppl; abstr 10067z).
279. Zage P.E., Kletzel M., Murray K., Marcus R., Castleberry R., Zhang Y., London W.B., Kretschmar C. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr. Blood Cancer 2008, 51:747-753.
280. Zhang H., Li Y., Lai M. The microRNA network and tumor metastasis. Oncogene 2010, 29:937-948.
281. Zimmerman K.A., Yancopoulos G.D., Collum R.G., Smith R.K., Kohl N.E., Denis K.A., Nau M.M., Witte O.N., Toran-Allerand D., Gee C.E., et al. Differential expression of myc family genes during murine development. Nature 1986, 319:780-783.